Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Currie

Showing results (191-200 of 231) with videos related to

Pageof 24
Sort By:
Mediators of Inflammation|January 1, 1995
Inducible nitric oxide synthase and guinea-pig ileitis induced by adjuvantN D Seago, J H Thompson, X J Zhang, et al.
Journal of Medicinal Chemistry|February 2, 1996
2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoformsW M Moore, R K Webber, K F Fok, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Rational selection of TbpB variants elucidates a bivalent vaccine formulation with broad spectrum coverage against <i>Neisseria gonorrhoeae</i>Jamie E Fegan, Epshita A Islam, David M Curran, et al.
Pharmacology Research & Perspectives|April 22, 2020
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in ratsAli R Banijamali, Andrew E Carvalho, James D Wakefield, et al.
United European Gastroenterology Journal|February 6, 2015
Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-CMichael Camilleri, Anthony J Lembo, Bernard J Lavins, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2012
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipationRobert W Busby, Marco M Kessler, Wilmin P Bartolini, et al.
Cellular Microbiology|November 20, 2008
An investigation of the expression and adhesin function of H7 flagella in the interaction of Escherichia coli O157 : H7 with bovine intestinal epitheliumArvind Mahajan, Carol G Currie, Shona Mackie, et al.
NPJ Vaccines|January 15, 2025
Rational selection of TbpB variants yields a bivalent vaccine with broad coverage against Neisseria gonorrhoeaeJamie E Fegan, Epshita A Islam, David M Curran, et al.
Cancer Research|October 4, 2000
Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMPK Shailubhai, H H Yu, K Karunanandaa, et al.
Neurogastroenterology and Motility|February 7, 2013
An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trialsJ E Macdougall, J M Johnston, B J Lavins, et al.
Pageof 24

Showing results (191-200 of 231) with videos related to

Sort By:
Pageof 24
Mediators of Inflammation|January 1, 1995
Inducible nitric oxide synthase and guinea-pig ileitis induced by adjuvantN D Seago, J H Thompson, X J Zhang, et al.
Journal of Medicinal Chemistry|February 2, 1996
2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoformsW M Moore, R K Webber, K F Fok, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Rational selection of TbpB variants elucidates a bivalent vaccine formulation with broad spectrum coverage against <i>Neisseria gonorrhoeae</i>Jamie E Fegan, Epshita A Islam, David M Curran, et al.
Pharmacology Research & Perspectives|April 22, 2020
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in ratsAli R Banijamali, Andrew E Carvalho, James D Wakefield, et al.
United European Gastroenterology Journal|February 6, 2015
Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-CMichael Camilleri, Anthony J Lembo, Bernard J Lavins, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2012
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipationRobert W Busby, Marco M Kessler, Wilmin P Bartolini, et al.
Cellular Microbiology|November 20, 2008
An investigation of the expression and adhesin function of H7 flagella in the interaction of Escherichia coli O157 : H7 with bovine intestinal epitheliumArvind Mahajan, Carol G Currie, Shona Mackie, et al.
NPJ Vaccines|January 15, 2025
Rational selection of TbpB variants yields a bivalent vaccine with broad coverage against Neisseria gonorrhoeaeJamie E Fegan, Epshita A Islam, David M Curran, et al.
Cancer Research|October 4, 2000
Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMPK Shailubhai, H H Yu, K Karunanandaa, et al.
Neurogastroenterology and Motility|February 7, 2013
An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trialsJ E Macdougall, J M Johnston, B J Lavins, et al.
Pageof 24